Colibri Heart Valve LLC v. Edwards Lifesciences: Federal Circuit Appeal Voluntarily Dismissed in Heart Valve Patent Dispute
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Colibri Heart Valve LLC v. Edwards Lifesciences Co. |
| Fallnummer | 24-1272 (Fed. Cir.) |
| Gericht | Federal Circuit (Appeal from PTAB/District Court) |
| Dauer | Dec 2023 – Mar 2024 84 Days |
| Ergebnis | Voluntary Dismissal — No Merits Ruling |
| Streitgegenständliches Patent | |
| Beschuldigte Produkte | Edwards Lifesciences’ TAVR Product Lines |
Fallübersicht
Die Parteien
⚖️ Kläger
Patent-holding entity asserting rights in transcatheter heart valve technology — an innovative delivery mechanism that eliminates the need for open-heart surgery.
🛡️ Beklagter
Among the world’s foremost structural heart disease companies, with deep commercial investments in transcatheter aortic valve replacement (TAVR) technology.
Streitgegenständliches Patent
This case centered on U.S. Patent No. 9,737,400 B2 — covering a percutaneously deliverable heart valve incorporating folded membrane cusps with integral leaflets — a technology area at the heart of a multi-billion-dollar medical device market.
- • US 9,737,400 B2 — Percutaneously deliverable heart valve featuring folded membrane cusps with integral leaflets.
Developing a medtech device?
Check if your heart valve design might infringe this or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
The Federal Circuit dismissed Case No. 24-1272 pursuant to Federal Rule of Appellate Procedure 42(b) upon joint stipulation of the parties on March 12, 2024. Each side agreed to bear its own costs. No damages were awarded, no injunctive relief was issued, and no precedential opinion was published. The underlying patent’s validity status following this dismissal is not publicly resolved by this proceeding alone.
Wichtige rechtliche Fragen
The designated verdict cause — Invalidity/Cancellation Action — indicates that Edwards Lifesciences mounted a challenge to the patentability of U.S. Patent No. 9,737,400 B2. Common grounds in such proceedings include obviousness (35 U.S.C. § 103), anticipation (35 U.S.C. § 102), or enablement/written description (35 U.S.C. § 112). The voluntary dismissal, agreed to by both parties, prevents any determination of which arguments were prevailing or failing at the appellate stage. Critically, an FRCP 42(b) dismissal at the Federal Circuit level does not constitute a ruling on the merits — leaving the underlying record’s outcome as the operative legal result for the patent’s validity posture.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in structural heart valve design. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- Alle zugehörigen Patente in diesem Technologiebereich anzeigen
- See which companies are most active in heart valve patents
- Muster der Anspruchsauslegung verstehen
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene Technologie oder Ihr eigenes Produkt durch.
- Geben Sie Ihre Produktbeschreibung oder technischen Merkmale ein.
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Aktives Patentrisiko
Percutaneous valve designs with folded cusps
Related Filings
Monitor for continuation patents
Strategischer Ausstieg
Negotiated settlement over judicial ruling
✅ Wichtigste Erkenntnisse
A joint Federal Circuit dismissal under FRCP 42(b) produces no precedential ruling and leaves underlying validity questions unresolved.
Verwandte Rechtsprechung suchen →The 84-day appellate lifespan signals active settlement negotiations likely began at or before the filing date in high-stakes medtech disputes.
Präzedenzfälle erkunden →Invalidity/cancellation appeals at the Federal Circuit remain viable leverage points for negotiating licensing outcomes.
Prozessstrategien analysieren →U.S. Patent No. 9,737,400 B2 remains a live patent asset requiring monitoring for any continuation filings or related family members.
Diese Patentfamilie überwachen →The case illustrates the value of early appellate settlement analysis in high-cost IP disputes, often preferable to prolonged uncertainty.
Abrechnungstrends analysieren →Häufig gestellte Fragen
The case involved U.S. Patent No. 9,737,400 B2 (Application No. 13/326,196), covering a percutaneously deliverable heart valve with folded membrane cusps and integral leaflets.
The parties jointly stipulated to dismissal under Federal Rule of Appellate Procedure 42(b), with each side bearing its own costs. No merits ruling was issued.
No. A voluntary dismissal under FRCP 42(b) does not constitute a ruling on patentability. The validity of U.S. Patent No. 9,737,400 B2 was not adjudicated by this Federal Circuit proceeding.
Companies operating in the medtech space, especially with percutaneous valve designs, can protect themselves by conducting robust freedom-to-operate (FTO) analysis before product launch, thoroughly documenting design evolution, developing design-around strategies for high-risk elements, and strategically filing their own patents. PatSnap Eureka’s FTO tools help R&D and IP teams identify potentially blocking patents before products go to market.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- United States Court of Appeals for the Federal Circuit — Case 24-1272
- U.S. Patent No. 9,737,400 B2 — Google Patents
- Cornell Legal Information Institute – Bundesvorschrift für Berufungsverfahren 42(b)
- PatSnap – Lösungen für den Umgang mit geistigem Eigentum für Anwaltskanzleien
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.